Roche Diagnostics launches Vitamin D total assay
Rotkreuz, 16 May 2011
With the launch of the Vitamin D total assay for the Elecsys analyzers and cobas modular platforms on May 13 in Europe as well as other regions including the CE mark Roche validates its leading position in medical value and testing efficiency. The Elecsys Vitamin D total assay is a fully automated assay delivering robust clinical results measuring both Vitamin D2 and Vitamin D3.
The Elecsys Vitamin D total assay is based on the biotin-streptavidin technology, standardized against the LC-MS-MS. Clinical evaluation validated the Elecsys Vitamin D total assay to generate excellent technical performance data and to demonstrate a high degree of comparability to the LC-MS-MS with a functional sensitivity of <5 ng/mL.1 Therefore, the Elecsys Vitamin D total assay is qualified to be the valuable diagnostic tool in the assessment of human Vitamin D sufficiency.
Increasing demands in Vitamin D testing has highlighted the widespread prevalence of vitamin D deficiency globally. “Big laboratories need reliable assays for Vitamin D analysis in order to perform high amounts of vitamin D tests in a short time period. The Elecsys Vitamin D total assay enables better clinical decision making, providing high confidence for patient results for high convenience and efficiency in laboratory medicine”, as Kay Brunner, Lifecycle Leader Cardio-Renal/Critical Care & Women’s Health of Roche Professional Diagnostics claims.
Vitamin D is a fat-soluble steroid hormone precursor that is mainly produced in the skin by exposure to sunlight and it is an important building block for human health. “Vitamin D deficiency plays a major role in bone metabolism disorders and is associated with many other diseases including cancer, cardiovascular heart diseases, and diabetes. Likewise, Vitamin D testing is needed for many people before starting Vitamin D supplementation and people who started supplementation, need to be monitored about their actual Vitamin D levels.
Roche Diagnostics will present the Elecsys Vitamin D total assay to the public during the Euromedlab exhibition days in Berlin from May 15-17. Visitors have the ability to attend to Roche Diagnostics’ expert sessions from May 16-17 to share clinical experience with the latest Elecsys Vitamin D total assay clinical studies presented by Derik Hermsen, Heinrich-Heine-University, Duesseldorf/Germany, Jos Wielders, Meander Medical Center, Amersfoort/The Netherlands, Robert Hawkins, Department of Laboratory Medicine, Tan Tock Seng Hospital/Singapore and Murat Oktem, Duzen Laboratories Group, Ankara/Turkey.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
Sources and references:
1) Data on file